IsoAid Wins Three-Year Brachytherapy Contract From Amerinet
September 19, 2008
IsoAid, a provider of brachytherapy products, and Amerinet, a healthcare group purchasing organization, have announced that IsoAid has been awarded a three-year brachytherapy contract to provide Amerinet members with a complete line of brachytherapy products used primarily in the treatment of prostate cancer.
The agreement will begin on October 1, 2008 and run for a three-year term. The agreement is said to offer Amerinet’s membership competitive market pricing, and access to IsoAid’s Advantage I-125 and Advantage Pd-103 seeds and related brachytherapy products.